Condition
Platinum-Sensitive Ovarian Cancer clinical trials and research
Research outlook What's coming for Ovarian cancer: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 4 Platinum-Sensitive Ovarian Cancer clinical trials that are recruiting, at sites in 10 countries (most in Japan (3), United States (3), Finland (2)). By phase: Phase 2 (2), Phase 3 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 10Countries
Newest Platinum-Sensitive Ovarian Cancer clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Rina-S with or without bevacizumab after platinum therapy for recurrent platinum-sensitive ovarian cancer | Phase 3 | Duarte, California and 11 other locations | Recruiting | May 4, 2026 |
| Rina-S plus standard care versus standard care as maintenance after second-line platinum chemotherapy for recurrent platinum-sensitive ovarian cancer | Phase 3 | Miami, Florida and 33 other locations | Recruiting | Nov 6, 2025 |
| IMGN151 alone or with carboplatin, olaparib, or bevacizumab for adults with high-grade serous gynecologic cancers | Phase 2 | Los Angeles, California and 20 other locations | Recruiting | Jun 17, 2025 |
| Combining AK112 with chemotherapy and Olaparib for ovarian cancer treatment | Phase 2 | Wuhan | Recruiting | Nov 13, 2024 |
All recruiting trials (4)
-
Rina-S with or without bevacizumab after platinum therapy for recurrent platinum-sensitive ovarian cancer
This trial tests whether Rina-S alone or with bevacizumab works better than the investigator’s choice platinum-based chemotherapy (with or without bevacizumab) for patients with recurrent platinum-sensitive ovarian cancer.
-
Rina-S plus standard care versus standard care as maintenance after second-line platinum chemotherapy for recurrent platinum-sensitive ovarian cancer
This trial will test whether adding Rina-S to standard maintenance care helps people with recurrent platinum-sensitive ovarian cancer stay cancer-free longer after second-line platinum chemotherapy.
-
IMGN151 alone or with carboplatin, olaparib, or bevacizumab for adults with high-grade serous gynecologic cancers
This trial tests whether IV IMGN151, given alone or with carboplatin, olaparib, or bevacizumab, can reduce disease activity and be safely tolerated in adults with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
-
Combining AK112 with chemotherapy and Olaparib for ovarian cancer treatment
This study is testing if a new drug called AK112, when combined with chemotherapy and Olaparib, can help women with certain types of ovarian cancer feel better and improve their treatment outcomes.
Related topics
Quick answers
How many Platinum-Sensitive Ovarian Cancer clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 10 countries. The most sites are in Japan (3 trials), United States (3 trials), Finland (2 trials), Israel (1 trial), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.